Jump to content

ISA

Expert (Moderator)
  • Content Count

    19
  • Joined

  • Last visited

  • Days Won

    1

ISA last won the day on June 26 2018

ISA had the most liked content!

Community Reputation

1 Neutral

2 Followers

Recent Profile Visitors

The recent visitors block is disabled and is not being shown to other users.

  1. Dengue vaccines have been under development since the 1940s, but due to the limited appreciation of global dengue disease burden and of the potential markets for dengue vaccines, the industry’s interest languished throughout much of the 20th century. In recent years, however, the development of dengue vaccines has accelerated dramatically. Sanofi Pasteur’s Dengvaxia® became the first dengue vaccine to be licensed for use in 2015. Today, several other vaccines are in various stages of advanced development, with clinical trials currently underway. Vaccine development for dengue is part
  2. Serie of questions and answers such as : What is RTS,S/AS01? What makes RTS,S different from malaria vaccine candidates currently under development? What is the efficacy of the RTS,S vaccine?
  3. The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of follow-up have been published previously. Herein, we report the final results from the same trial, including the efficacy of a booster dose.
  4. This document takes into account new and unpublished data that were communicated by Sanofi Pasteur to WHO in November-December 2017. WHO published the recommendations of the Strategic Advisory Group of Experts on Immunization (SAGE) on the use of Dengvaxia® on 27 May 2016 (1), and subsequently a WHO position paper on dengue vaccine on 29 July 2016 (2). Following the disclosure to WHO of new data on Dengvaxia® by its manufacturer, Sanofi Pasteur, as described in more detail below, WHO has initiated a process engaging independent external experts to review the data in detail. This proc
  5. The reconvened Dengue Working Group is asked to review new data on the long-term follow-up of dengue vaccine recipients. This includes data generated by further laboratory testing and analysis related to the long-term safety and efficacy of CYD-TDV Phase 3 trial participants. In particular, the group is asked to review the differential performance of the CYD-TDV vaccine (also known as Dengvaxia®) in subjects seronegative versus seropositive at the time of vaccination. The group is asked to advise on a revision of WHO’s current vaccine recommendations as published in July 2016. The review at SA
  6. WHO published the recommendations of the Strategic Advisory Group of Experts on Immunization (SAGE) on the use of Dengvaxia® on 27 May 2016, and subsequently a WHO position paper on dengue vaccine on 29 July 2016. Following the disclosure of new data on Dengvaxia® by its manufacturer, Sanofi Pasteur, on 29 November 2017 (as described in more detail below), WHO`s Global Advisory Committee on Vaccine Safety (GACVS) and the WHO Secretariat published interim statements on December 7, 2017, and December 22, 2017, respectively. WHO initiated a process engaging independent external experts to re
  7. At the November 2011 meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization, SAGE noted with concern the impact of reluctance to accept immunization on the uptake of vaccines reported from both developed and developing countries. These reports led SAGE to request the establishment of a working group on vaccine hesitancy. Vaccine hesitancy refers to delay in acceptance or refusal of vaccines despite availability of vaccination services. Vaccine hesitancy is complex and context specific varying across time, place and vaccines. It includes factors such as complacency, co
  8. This page is aimed at providing a listing of existing vaccinology training courses, of varying durations and training modalities (in-person, online, blended), and an easy search process for interested parties looking for a vaccinology course and identifying alternative courses. The information provided on each course at the respective links is the sole responsibility of the persons in charge of their respective websites/courses. The listing of a vaccinology course on this page does not mean an endorsement of its content or any certification of the quality of the teaching approach. All
  9. For most readers of “Vaccine,” it is a truism that vaccines represent one of the safest and most effective tools available in global efforts to control and prevent infectious diseases. Yet, parents searching the Internet about whether or not it is safe to get themselves or their children vaccinated will find this consensus recast as a controversy, or even a conspiracy. Many of the top internet search results question or dispute the scientific consensus about the safety and effectiveness of some or all vaccine son a number of grounds, from secular to religious to political-philosophical. The ga
  10. The SAGE Working Group on Vaccine Hesitancy concluded that vaccine hesitancy refers to delay in acceptance or refusal of vaccination despite availability of vaccination services. Vaccine hesitancy is complex and context specific, varying across time, place and vaccines. It is influenced by factors such as complacency, convenience and confidence. The Working Group retained the term ‘vaccine’ rather than ‘vaccination’ hesitancy,although the latter more correctly implies the broader range of immunization concerns, as vaccine hesitancy is the more commonly used term. While high levels of hesitancy
  11. While most people vaccinate according to the recommended schedule, this success is challenged by individuals and groups who delay or refuse vaccines. The aim of this article is to review studies on vaccine hesitancy among healthcare providers (HCPs), and the influences of their own vaccine confidence and vaccination behaviour on their vaccination recommendations to others. The search strategy was developed in Medline and then adapted across several multidisciplinary mainstream databases including Embase Classic & Embase, and PschInfo. All foreign language articles were included
×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue. - Terms of Use - Privacy Policy - Guidelines